Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma

Abstract

BACKGROUND Spenic hemangiosarcoma (HSA) in dogs treated with surgery alone is associated with short survival times, and the addition of doxorubicin (DOX) chemotherapy only modestly improves outcome. The purpose of this study was to evaluate the impact of toceranib administration on progression free survival in dogs with stage I or II HSA following… (More)
DOI: 10.1186/s12917-015-0446-1

Topics

4 Figures and Tables

Cite this paper

@inproceedings{Gardner2015MaintenanceTW, title={Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma}, author={Heather L. Gardner and Cheryl A. London and Roberta A. Portela and Sandra L Nguyen and Mona P. Rosenberg and Mary Kay Klein and Craig Clifford and Douglas H. Thamm and David M. Vail and Phil Bergman and Martin Crawford-Jakubiak and Carolyn S. Henry and Jennifer Ann Locke and Laura D. Garrett}, booktitle={BMC veterinary research}, year={2015} }